Integrative single-cell RNA-seq and spatial transcriptomics analyses reveal diverse apoptosis-related gene expression profiles in EGFR-mutated lung cancer

In EGFR -mutated lung cancer, the duration of response to tyrosine kinase inhibitors (TKIs) is limited by the development of acquired drug resistance. Despite the crucial role played by apoptosis-related genes in tumor cell survival, how their expression changes as resistance to EGFR-TKIs emerges re...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cell death & disease Ročník 15; číslo 8; s. 580 - 11
Hlavní autoři: Izumi, Motohiro, Fujii, Masanori, Kobayashi, Ikei S., Ho, Vivian, Kashima, Yukie, Udagawa, Hibiki, Costa, Daniel B., Kobayashi, Susumu S.
Médium: Journal Article
Jazyk:angličtina
Vydáno: London Nature Publishing Group UK 09.08.2024
Springer Nature B.V
Nature Publishing Group
Témata:
ISSN:2041-4889, 2041-4889
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:In EGFR -mutated lung cancer, the duration of response to tyrosine kinase inhibitors (TKIs) is limited by the development of acquired drug resistance. Despite the crucial role played by apoptosis-related genes in tumor cell survival, how their expression changes as resistance to EGFR-TKIs emerges remains unclear. Here, we conduct a comprehensive analysis of apoptosis-related genes, including BCL-2 and IAP family members, using single-cell RNA sequence ( scRNA-seq) and spatial transcriptomics (ST). scRNA-seq of EGFR -mutated lung cancer cell lines captures changes in apoptosis-related gene expression following EGFR-TKI treatment, most notably BCL2L1 upregulation. scRNA-seq of EGFR -mutated lung cancer patient samples also reveals high BCL2L1 expression, specifically in tumor cells, while MCL1 expression is lower in tumors compared to non-tumor cells. ST analysis of specimens from transgenic mice with EGFR-driven lung cancer indicates spatial heterogeneity of tumors and corroborates scRNA-seq findings. Genetic ablation and pharmacological inhibition of BCL2L1 /BCL-XL overcome or delay EGFR-TKI resistance. Overall, our findings indicate that BCL2L1 /BCL-XL expression is important for tumor cell survival as EGFR-TKI resistance emerges.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2041-4889
2041-4889
DOI:10.1038/s41419-024-06940-y